摘要
目的:观察利妥昔单抗联合盐酸吉西他滨和奥沙利铂(R-GEMOX)治疗复发或难治性弥漫大B细胞淋巴瘤的疗效和毒副反应。方法:利妥昔单抗375mg/m2化疗前1天静脉滴入,吉西他滨1000mg/m2,静脉滴入d1,d8,奥沙利铂130mg/m2,静脉滴入d2,以3周为1个化疗周期,3周期后评价临床疗效。结果:11例患者中,完全缓解(CR)3例,部分缓解(PR)4例。1例稳定(SD),3例进展(PD)。总缓解率为63.6%。化疗毒副反应主要为轻度的胃肠道反应,少数患者出现轻度的骨髓抑制,如白细胞及血小板减少。结论:利妥昔单抗联合盐酸吉西他滨和奥沙利铂(R-GEMOX)对复发或难治性进展型弥漫大B细胞淋巴瘤有较好的近期疗效,大部分患者可以承受其毒性,是一个值得进一步验证的补救性化疗方案。
Objective： To evaluate the response rates and toxicities of rituximab , gemcitabine and oxaliplatin （ R -GEMOX） for the treatment of relapsed or refractory diffuse large B -cell lymphoma. Methods： Rituximab 375 mg/m^2 intravenously （iv） do, gemcitabine 1000 mg/m^2 on day 1 and 8, and oxaliplatin 130 mg/m^2 iv on day 2, every 21 days. Clinical response was assessed after 3 cycles of chemotherapy. Results：In the 11 cases, the complete re- sponse was 3 cases, partial response 4 cases, 1 ease was no change,3 cases were progressive,the overall response rate （ CR ＋ PR） was 63.6%. Drug related toxic effects were mild gastrointestinal reactions in most patients and mild bone marrow depression in few patients such as neutropenia, thrombocytopenia. Conclusion： R -GEMOX regimen possesses better short - term efficacy and acceptable toxicity. This protocol is worthy to be warranted as salvage for relapsed or ref rectory diffuse large B - cell lymphoma.
出处
《现代肿瘤医学》
CAS
2012年第11期2376-2378,共3页
Journal of Modern Oncology
